Royalty Pharma Reports Q4 and Full Year 2023 Results
February 15, 2024 07:30 ET
|
Royalty Pharma plc
Portfolio Receipts of $736 million in Q4 2023 and $3,049 million for FY 2023Net cash provided by operating activities of $773 million in Q4 2023 and $2,988 million for FY 2023Announced transactions of...
Royalty Pharma To Announce Fourth Quarter And Full Year 2023 Financial Results On February 15, 2024
January 30, 2024 16:15 ET
|
Royalty Pharma plc
NEW YORK, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth quarter and full year 2023 financial results on Thursday, February 15,...
Royalty Pharma Announces Dividend Increase
January 19, 2024 08:15 ET
|
Royalty Pharma plc
NEW YORK, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2024 of $0.21 per Class A...
Royalty Pharma Highlights Accomplishments and Provides Business Update at 42nd Annual J.P. Morgan Healthcare Conference
January 08, 2024 07:00 ET
|
Royalty Pharma plc
2023 Portfolio Receipts expected to be approximately $3,050 million, exceeding the upper end of guidance rangeAnnounced transactions of $13 billion since 2020 expected to add approximately $1.2...
Royalty Pharma to Present at the Evercore ISI 6th Annual HealthCONx Conference
November 27, 2023 16:15 ET
|
Royalty Pharma plc
NEW YORK, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at the Evercore ISI 6th Annual HealthCONx...
Royalty Pharma and Teva Collaborate to Further Accelerate Olanzapine Lai Program
November 13, 2023 08:10 ET
|
Royalty Pharma plc
Royalty Pharma to provide R&D funding support of up to $125 million for the development of olanzapine LAI (TEV-‘749), a long-acting subcutaneous injectable olanzapine for schizophreniaPhase 3 data...
Royalty Pharma Reports Third Quarter 2023 Results
November 08, 2023 07:00 ET
|
Royalty Pharma plc
Net cash provided by operating activities (GAAP) of $574 million and Adjusted Cash Receipts(1) (non-GAAP) of $637 millionAnnounced transactions of up to $3.8 billion year-to-date, including $2.1...
Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics’ Royalty on Evrysdi
October 19, 2023 07:59 ET
|
Royalty Pharma plc
Royalty Pharma purchases a portion of royalties on Roche’s Evrysdi for $1.0 billion upfrontPTC Therapeutics has option to sell rest of royalty for up to $500 million; Royalty Pharma has option to buy...
Royalty Pharma Declares Fourth Quarter 2023 Dividend
October 16, 2023 16:15 ET
|
Royalty Pharma plc
NEW YORK, Oct. 16, 2023 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2023 of $0.20 per Class A...
Royalty Pharma To Announce Third Quarter 2023 Financial Results On November 8, 2023
October 11, 2023 16:15 ET
|
Royalty Pharma plc
NEW YORK, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2023 financial results on Wednesday, November 8, 2023 before the...